Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

Integra Lifesciences Holdings (IART) Receivables - Net (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Receivables - Net for 17 consecutive years, with $278.8 million as the latest value for Q4 2025.

  • Quarterly Receivables - Net rose 2.38% to $278.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $278.8 million through Dec 2025, up 2.38% year-over-year, with the annual reading at $278.8 million for FY2025, 2.38% up from the prior year.
  • Receivables - Net hit $278.8 million in Q4 2025 for Integra Lifesciences Holdings, up from $262.2 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $284.5 million in Q2 2025 to a low of $222.2 million in Q3 2021.
  • Historically, Receivables - Net has averaged $251.5 million across 5 years, with a median of $253.2 million in 2023.
  • Biggest YoY gain for Receivables - Net was 28.29% in 2021; the steepest drop was 8.96% in 2021.
  • Year by year, Receivables - Net stood at $231.8 million in 2021, then grew by 13.65% to $263.5 million in 2022, then fell by 1.57% to $259.3 million in 2023, then rose by 5.03% to $272.4 million in 2024, then grew by 2.38% to $278.8 million in 2025.
  • Business Quant data shows Receivables - Net for IART at $278.8 million in Q4 2025, $262.2 million in Q3 2025, and $284.5 million in Q2 2025.